Literature DB >> 6538340

In vitro immunoglobulin production by peripheral blood mononuclear cells from multiple myeloma patients and patients with benign monoclonal gammopathy. Regulation by cell subsets.

D Peest, U Brunkhorst, I Schedel, H Deicher.   

Abstract

Peripheral blood mononuclear cells (PBM) from four patients with IgG myeloma and four patients with benign monoclonal gammopathy (BMG) were stimulated with pokeweed mitogen (PWM), and the in vitro immunoglobulin production over 7 days was measured with an enzyme-linked immunosorbent assay. All myeloma patients were sufficiently treated with cytostatic drugs. Their PBM did not produce monoclonal Ig in vitro, as opposed to PBM from two patients with BMG. Unseparated PBM from myeloma patients produced smaller amounts of polyclonal Ig than unseparated cells from normal donors. However, macrophage-depleted PBM from myeloma patients produced amounts of Ig comparable to those of normal donors when autologous or allogeneic adherent cells were returned in defined numbers. T cells from three of the four myeloma patients could provide help for the Ig production by B cells from healthy donors. These results indicate that functionally normal polyclonal B cells circulate in the blood of myeloma patients. The circulating T-cell population also has no obvious defect. In contrast, blood macrophages seemed to be altered with respect to their regulating function for polyclonal Ig production. The results obtained by using cell populations from patients with BMG did not differ from those of healthy people.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538340     DOI: 10.1111/j.1365-3083.1984.tb00911.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  Antigen stimulated IgM secretion by circulating B lymphocytes in patients with benign and malignant IgG gammopathy. Relationship to stage of disease.

Authors:  S Pollack; R Katz; I Tatarsky; A Carter
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

2.  Regulation of the in vitro monoclonal immunoglobulin production in cultures of peripheral blood mononuclear cells and bone marrow cells from myeloma patients mediated by T cell dependent mitogens.

Authors:  D Peest; S Gasch; C Thiele; B Bartels; U Brunkhorst; I Dallmann; M Hoffmann; I Schedel; H Deicher
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

3.  Suppression of polyclonal B cell proliferation mediated by supernatants from human myeloma bone marrow cell cultures.

Authors:  D Peest; R Hölscher; R Weber; R Leo; H Deicher
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

4.  Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels.

Authors:  L M Pilarski; B A Ruether; M J Mant
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

5.  Spontaneous and pokeweed mitogen induced production of rheumatoid factor and immunoglobulins in type II essential mixed cryoglobulinaemia.

Authors:  R A Sinico; G Fiorini; A Fornasieri; P Bernasconi; S Benuzzi; M L Paracchini; G D'Amico
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

6.  Regulation of immunoglobulin synthesis by monocytes in multiple myeloma and benign monoclonal gammopathy.

Authors:  A Takeshita
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

7.  Endothelial cell enhancement of PWM induced immunoglobulin synthesis by peripheral blood mononuclear cells.

Authors:  M A King; W R Roche; D S Nelson
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

8.  The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow.

Authors:  J W Croese; C M Vas Nunes; J Radl; M H van den Enden-Vieveen; R J Brondijk; W J Boersma
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.